Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer

Clicks: 57
ID: 302510
2007
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #4 of 372 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 372 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BackgroundWomen with HER2–overexpressing breast cancers have poor prognosis, and many are resistant to the HER2 monoclonal antibody trastuzumab. A subgroup of HER2–overexpressing tumors also express p95HER2, an amino terminally truncated receptor that has kinase activity. Because p95HER2 cannot bind to trastuzumab but should be responsive to the HER2 tyrosine kinase inhibitor lapatinib, we compared the sensitivity of tumors expressing p95HER2 and tumors expressing the full-length HER2 receptor to these agents.
Reference Key
openalex_W2172265576 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Maurizio Scaltriti, Federico Rojo, Alberto Ocaña, Judit Anido, Marta Guzmán, Javier Cortés, Serena Di Cosimo, Xavier Matías‐Guiu, Santiago Ramón y Cajal, Joaquı́n Arribas, José Baselga
Journal JNCI Journal of the National Cancer Institute
Year 2007
DOI
10.1093/jnci/djk134
URL
https://academic.oup.com/jnci/article-pdf/99/8/628/7689446/djk134.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.